Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
about
Maintenance therapy with all-trans retinoic acid and arsenic trioxide improves relapse-free survival in adults with low- to intermediate-risk acute promyelocytic leukemia who have achieved complete remission after consolidation therapy.LG-362B targets PML-RARα and blocks ATRA resistance of acute promyelocytic leukemia.All-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis.The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy.Combining retinoic acid and oral arsenic may be potentially the first-line therapy for non-high-risk acute promyelocytic leukemia.Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives.Current standard treatment of adult acute promyelocytic leukaemia.Current management of newly diagnosed acute promyelocytic leukemia.Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.A mouse model for embryonal tumors with multilayered rosettes uncovers the therapeutic potential of Sonic-hedgehog inhibitors.Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial
P2860
Q33631350-FD08226B-9F59-4A73-8673-9912ECA82506Q35969759-4D310C81-72A4-4E67-AA6B-A23777F41008Q36070904-3B9037D4-7F79-43ED-9CB6-D05C79A609D6Q37296118-C24E93A1-AC4B-49EC-AAEA-C8F84A94B937Q37574635-A95A3F75-5278-420D-9BBD-137E5341F5C6Q37712353-A01E072A-EC89-492D-954A-4CC18E42F863Q38674575-B6DD60FA-8096-42EE-9D80-CEA575A8FE45Q38809825-4EC1C530-F4CE-4253-B198-0B84213967C2Q39023642-2681930A-A1DD-4FB3-8DF4-551FA86260E8Q47823690-EDAA0A12-0349-43D3-BAE2-62FBE661012AQ55282056-B7EB2FED-885D-47D4-AB7D-1185F4D67401Q58763229-FADFBCB0-16EA-46B4-A9F7-5ABE115B154B
P2860
Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Use of arsenic trioxide in rem ...... non-randomised phase 2 trial.
@en
type
label
Use of arsenic trioxide in rem ...... non-randomised phase 2 trial.
@en
prefLabel
Use of arsenic trioxide in rem ...... non-randomised phase 2 trial.
@en
P2093
P1476
Use of arsenic trioxide in rem ...... a non-randomised phase 2 trial
@en
P2093
Alberto Catalano
Amanda Hugman
Andrew Grigg
Australasian Leukaemia and Lymphoma Group
Frank Firkin
Harry J Iland
John Bashford
John F Seymour
John Moore
P304
P356
10.1016/S2352-3026(15)00115-5
P577
2015-08-20T00:00:00Z